Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Androgen Ablation in Metastatic Prostate Cancer
NCT01630590Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2014
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression Free Survival at 31.2 months and Serious Adverse Events and Other Adverse Events up to 80 months. Started Jan 2014; status: completed.
02
Drugs
cabozantinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01630590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630590.